Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Intervalo de ano de publicação
1.
Clin Obstet Gynecol ; 67(2): 418-425, 2024 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-38597187

RESUMO

In 2003, in the context of a national research funding program in which obstetric research was prioritized, several perinatal centers took the initiative to jointly submit a number of applications to the subsidy programs of Effectiveness Research and Prevention of ZonMw. This has led to the funding of the Obstetric Consortium with several projects, including the "Hypertension in Pregnancy Intervention Trial At Term" and the "Disproportionate Intrauterine Growth Intervention Trial At Term" studies. The studies showed that induction of labor for hypertension and growth restriction at term was the appropriate management. Subsequent implementation improved maternal and perinatal outcomes.


Assuntos
Retardo do Crescimento Fetal , Hipertensão Induzida pela Gravidez , Humanos , Gravidez , Feminino , Retardo do Crescimento Fetal/prevenção & controle , Hipertensão Induzida pela Gravidez/prevenção & controle , Hipertensão Induzida pela Gravidez/terapia , Trabalho de Parto Induzido/métodos , Recém-Nascido
2.
J Reprod Immunol ; 160: 104141, 2023 12.
Artigo em Inglês | MEDLINE | ID: mdl-37708725

RESUMO

OBJECTIVES: The risk of preterm preeclampsia (PT PE) can significantly be reduced by starting acetylsalicylic acid ≤ 16 weeks of gestational age. First trimester predictive models based on maternal risk factors to effectively start this therapy lacked sufficient power, but recent studies showed that these models can be improved by including test results of biochemical and/or -physical markers. To investigate whether testing a biochemical marker in the first trimester is cost-effective in the Netherlands, a cost-effectiveness analysis was performed in this study. STUDY DESIGN: The outcome of this study was expressed as an incremental cost-effectiveness ratio (ICER) with as effect prevented PT PE cases. To evaluate the impact of each model parameter and to determine model uncertainties, both univariate and probabilistic sensitivity analyses were performed. RESULTS: When compared to the baseline strategy, the test strategy is estimated to save almost 4 million euros per year on a national scale and at the same time this would prevent an additional 228 PT PE cases. The sensitivity analyses showed that the major drivers of the result are the costs to monitor a high-risk pregnancy and the specificity and that most of the model simulations were in the southeast quadrant: cost saving and more prevented complications. CONCLUSIONS: This study showed that a first-trimester test strategy to screen for PT PE in the first trimester is potentially cost-effective in the Dutch healthcare setting. The fact that the specificity is a major driver of the ICER indicates the importance for a (new) screening model to correctly classify low-risk pregnancies.


Assuntos
Pré-Eclâmpsia , Gravidez , Recém-Nascido , Feminino , Humanos , Pré-Eclâmpsia/diagnóstico , Pré-Eclâmpsia/prevenção & controle , Primeiro Trimestre da Gravidez , Análise de Custo-Efetividade , Países Baixos , Aspirina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA